Preclinical evaluation of the theranostic potential of 89Zr/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model

In this study by Wu et al., PET and SPECT imaging were applied to evaluate a newly developed TROP-2–targeted antibody (NY003) in a triple-negative breast cancer (TNBC) mouse model. For this, the antibody was radiolabeled with zirconium-89 for PET and lutetium-177 for SPECT and radioimmunotherapy. SPECT imaging was performed using the Ɣ-CUBE (SPECT) to enable in vivo monitoring of TROP-2 targeting.